Nothing destroys confidence in a regulatory agency faster than the perception that it has lost sight of its mission. The Food and Drug Administration exists not merely to keep unsafe drugs off the market, but also to ensure that lifesaving treatments reach patients before it is too late. President Trump’s “Right to Try” initiative reflected a recognition that when Americans are confronting terminal or degenerative illnesses, regulators should lean toward speed, flexibility, and informed patient choice rather than procedural paralysis.
However, it’s not clear that Trump’s appointees at the FDA are even aware of this initiative.
Read Full Article »
